Mark Lundquist, PhD

Mark Lundquist, PhD has extensive work experience in the field of biology and research. Mark is currently serving as the Associate Director of Biology at Alphina Therapeutics since August 2022. Prior to this, they worked at Kadmon, a Sanofi Company, as a Senior Scientist from November 2018 to July 2022.

Before their tenure at Kadmon, Mark had multiple roles at Weill Cornell Medicine. Mark served as an Instructor at the Meyer Cancer Center from June 2018 to October 2018. Prior to that, they worked as a Postdoctoral Researcher at the Meyer Cancer Center (Cantley Lab) from June 2012 to May 2018. Mark also served as a PhD Candidate at the Department of Pharmacology (Jaffrey Lab) from 2005 to May 2012.

Additionally, Mark worked as a Risk Analyst at USACHPPM, U.S. Dept. of Defense from August 2003 to May 2005.

Overall, Mark Lundquist, PhD has a strong background in biology, with experience in various research roles and expertise in cancer research.

Mark Lundquist, PhD completed their Bachelor of Science in Chemical Engineering at the University of Pennsylvania, although the specific start and end years are not provided. Mark then pursued a Masters in Biotechnology at The Johns Hopkins University, with no specific timeframe mentioned. Afterward, Mark attended the Weill Cornell Graduate School of Medical Sciences, where they obtained their PhD in Pharmacology in 2012. Currently, they are pursuing an MBA at Columbia Business School, set to be completed between 2021 and 2023.